Literature DB >> 31999290

Shuttle/sink model composed of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells.

Jianhua He1, Yun Yang2, Xiaoju Zhou3, Wenli Zhang1, Jianping Liu1.   

Abstract

Targeting drug delivery to macrophage/foam cells is challenged owing to the poor cell permeability and fluidity resulting from the massive accumulation of intracellular cholesterol in atherosclerosis (AS). Discoidal reconstituted high-density lipoprotein (d-rHDL) has been well regarded as a potential drug delivery system for AS by virtue of its plaque-targeting and cholesterol removal abilities, while the latter is compromised by the high activation energy of cholesterol efflux. It is reported that a low concentration of β-cyclodextrin (β-CD) can function as a cholesterol shuttle to promote cholesterol efflux from cells to the extracellular acceptors (cholesterol sink, such as HDL particles), but it is still unknown whether the combination of β-CD with a drug-loaded d-rHDL can function as a shuttle/sink model to promote the remodeling and drug release of the d-rHDL carrier after accelerating the cholesterol efflux. Furthermore, it is interesting to investigate whether enhanced cholesterol efflux can improve the cellular drug uptake by restoring the permeability and fluidity of the cell membrane. Here, simvastatin-loaded d-rHDL (ST-d-rHDL) was combined with different concentrations of β-CD. Compared with ST-d-rHDL alone, the cholesterol removal ability of ST-d-rHDL combined with 0.5 mM of β-CD increased by 31-fold after incubation for 6 h and the cumulative drug release of ST-d-rHDL increased by two-fold during the initial 1 h in an acellular mimetic system. In macrophage/foam cells, 0.5 mM of β-CD showed superior promoting effects in the cholesterol removal ability and remodeling of ST-d-rHDL compared to 0.1 mM of β-CD. The high concentration of β-CD at 2 mM displayed a low efficiency for accelerating cholesterol efflux, which might function as a cholesterol sink rather than a cholesterol shuttle. Moreover, the permeability and fluidity of the cell membrane were improved by combining 0.5 mM of β-CD with ST-d-rHDL, which exhibited an enhanced cellular drug uptake and inhibiting effect on the intracellular lipid deposition and secretion of inflammatory cytokine. Collectively, combination of β-CD and ST-d-rHDL as a shuttle/sink model could enhance cholesterol efflux and drug uptake to suppress inflammation in macrophage/foam cells.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31999290     DOI: 10.1039/c9tb02101a

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  5 in total

1.  HDL and Therapy.

Authors:  Ke Li; Xianwei Xie; Yansong Guo
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.

Authors:  Jianhua He; Wenli Zhang; Xiaoju Zhou; Fengfei Xu; Jiahui Zou; Qiqi Zhang; Yi Zhao; Hongliang He; Hu Yang; Jianping Liu
Journal:  Bioact Mater       Date:  2022-04-07

3.  Exploring In Vitro Biological Cellular Responses of Pegylated β-Cyclodextrins.

Authors:  Juliana Rincón-López; Miguelina Martínez-Aguilera; Patricia Guadarrama; Karla Juarez-Moreno; Yareli Rojas-Aguirre
Journal:  Molecules       Date:  2022-05-08       Impact factor: 4.927

Review 4.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

Review 5.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.